June 27, 2019 – New York, US – Antibodies have high specificity and affinity for the corresponding antigens with low toxicity and side effects, so they have obvious specific advantages in the diagnosis and treatment of diseases. Therapeutic monoclonal antibody drugs have become the most widely used biotechnological drugs and the largest type of sales, surpassing erythropoietin, insulin and interferon products, which are of great research and medical significance. In order to accelerate and perfect the analysis procedures of projects from customers, Creative Biolabs has provided a variety of services with its advanced platforms and in silico methods, which include Epitope-specific Antibody Design, Structure-based Antibody Reformatting, Antibody Developability Prediction, etc.
1. Creative Biolabs’ novel epitope-specific mAbs design service, mainly composed of antibody structure modelling, antibody-antigen complex analysis, computer-aided affinity maturation, antibody structure determination, and experimental validation, is built upon a rational strategy that is peer-reviewed protein engineering algorithm. All of the analysis methods help to produce antibody to target specific epitopes within a protein, even when the epitopes are not effective antigens.
2. In silico techniques are adopted in the structure-based antibody reformatting service to obtain ideal antibody fragments with stability, affinity and preeminent specificity. With techniques like homology modeling, molecular dynamics simulation, in-house algorithm, antibody molecule model analysis, identifying the main residues that affect target antibody feature becomes possible, after which it is operable to appropriately make mutations on the residues for changing the properties of antibody. The significance of the process lies in maintaining antibody physicochemical property stable and its original affinity and function unchanged. Essential sub-sectors of antibody reformatting service include Variable Region Engineering for Reformatting and Reformat into scFv and VHH.
3. Another essential component of therapeutic antibody design is antibody developability prediction, which is fulfilled after a series of small-size, quick tests of prediction plus in silico analysis to figure out both biochemical and biophysical features of the clinical candidate molecule at the preliminary stage of drug development. Aiming to enhance the procedure, Creative Biolabs has built a technological platform, based upon which antibody aggregation prediction and antibody immunogenicity prediction can be possessed utilizing principal analysis methods including N-Glycosylation Sites and Cysteines in Fv Domains Analysis, Lysine Glycation Sites Analysis, Isoelectric Point and Charge Distribution Analysis, Prediction of Asparagine and Aspartate Degradation Hotspots in Fv Domains Analysis, Immunogenicity Analysis and so on.
For years, Creative Biolabs has been working on the improvement and perfectness of antibody design procedures. With experienced scientists and the latest analytical techniques as well as wholesome in silico methods, therapeutic antibody design projects of clients can be prompted with less economy expenditure but high efficiency.
About Creative Biolabs:
Creative Biolabs is the leading custom service provider that has extensive experience in various antibody production and engineering fields, which is also professional in conducting in depth antibody humanization and affinity maturation using phage display and DNA mutagenesis approaches with services covering bacterial production of scFv, diabody, tandem scFv, miniantibody and Fab, and mammalian cell expression of minibody, chimeric IgG and IgG, etc.
Details can be found at https://www.creative-biolabs.com/preciab/.
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Address:45-1 Ramsey Road
State: New York
Country: United States